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Abstract

Treatment of L5178Y in vitro cells with ara-c (10
M)
or asparaginase (0.5 lU/ml) for" "8 hours resulted, in 45%
and 24% viability, respectively; simultaneous exposure
to both drugs resulted in 25% viability, a subadditive ef¬
fect. Sequential 8 hour treatments with asparaginase
preceding ara-c or ara-c preceding asparaginase resulted
in 43% and 8% viability, respectively, indicating strong
schedule-dependency. While ara-c pretreatment resulted
in cell synchronization it did not enhance asparaginaseinduced inhibition of DNA and protein synthesis. In vivo
recovery from drug-induced inhibition of cell growth suggested
an optical interval of 120 hours. Mice were inoculated
with 10 cells. Treatment with asparaginase, ara-c or both
drugs on day 3 resulted in mean survival times (MST) of 16,
21 and 18 days, respectively (control MST 10 days). With
a 120 hour interval between the 2 drugs, asparaginase
preceding ara-c resulted in a MST of 23 days; ara-c preceding
asparaginase produced 20/24 60 day survivors. Maximal weight
loss was only 10%. Mechanisms for the antagonism include
asparaginase-induced decreased transport and incorporation
of ara-c into macromolecules and cytokinetic mistiming.
Unequivocal understanding of the apparent synergy is not
adequately explained by the observed AC-induced synchronization.
Since both drugs are likely components of antileukemic
combinations, understanding of such drug-drug interactions would
optimize clinical therapy.
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Introduction

A variety of drug interactions, ranging from antagonism to
synergism, can result from the combination of two cancer chemothera¬
peutic agents.

There is a growing interest in understanding the

basis of these interactions since various studies have indicated
the superiority of combination therapy for the treatment of acute
leukemia (34, 40, 46, 60, 114, 125, 150).

Two agents that have been

studied for remission induction in acute lymphocytic and acute
myelogenous leukemia are cytosine arabinoside (ara-c) and L-asparaginase (9, 54, 112, 144).

Even though their combined use has pro¬

duced encouraging results in the therapy of acute lymphocytic leu¬
kemia (46, 60, 114, 125), few studies have attempted to determine
the optimal schedule of administration or to define the nature of
their interactions.
An aim in designing combination chemotherapy is to select
agents which will maximize tumor cell kill while minimizing host
toxicity.

This can be accomplished with agents like ara-c and

asparaginase, which have different host toxicities (9, 54, 101).
This will work, of course, provided that their interaction does not
antagonize their antitumor activity as, for example, asparaginase
antagonizing the cytotoxicity of another chemotherapeutic agent,
methotrexate (22, 23, 25).

Capizzi et al. (22, 23, 25) demonstrated
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both schedule dependent synergism and antagonism for the combination
of asparaginase and methotrexate.

In brief, when asparaginase

preceded methotrexate by less than 2H hours, the effect of metho¬
trexate on murine leukemia L5178Y cells was diminished.

However,

when the reverse combination was tried, there was no antagonism.
In fact, asparaginase protects mice against methotrexate-induced
intestinal lesions when asparaginase followed methotrexate.

From

this work it can be concluded that there is a synergistic antitumor
schedule that also minimizes host toxicity.
Although methotrexate and ara-c have different intracellular
mechanisms of action (22, 25, 55, 75, 82, 165) they are both active
agents in inhibiting DNA synthesis.

Therefore, the main purpose of

this thesis project was to determine if the combination of ara-c
and asparaginase also exhibits schedule-dependency.

Studies reported

in this thesis describe the effect of three different treatment sched¬
ules on animal survival and cell viability ±n_ vitro using the animal
tumor model, murine leukemia L5173Y.

In addition, in an attempt

to explain the interactions observed, the effect of this combina¬
tion of drugs on DNA and protein synthesis was also investigated.

5
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Literature Review

Cytosine Arabinoside

Ara-c (cytosine arabinoside, 1-B-D arabinofuranosylcytosine,
Cytosar, Cytarabine) is a pyrimidine nucleoside analog of deoxycytidine, but differing in that the sugar moiety is arabinose
rather than deoxyribose (95, 102).

Ara-c is of considerable clinical

importance because of its effectiveness against acute leukemia—
particularly the acute myelogenous form—in man (9, 54).

The

brief review presented here will summarize some of the aspects of
ara-c's cellular uptake, intracellular mechanism of action, and
clinical use.
Ara-c passively diffuses into cells, where it is rapidly
phosphorylated to the active form, ara-CTP (29, 31s 79, 104).

In¬

deed, there appears to be a relationship between the ability of
human and mouse leukemic cells to retain ara-c in its phosphorylated
form, and the susceptibility of the cells to the drug (29, 79)•
On the other hand, resistance of cells to ara-c has been correlated
with decreased levels of deoxycytidine kinase (136), the enzyme
responsible for the phosphorylation of both ara-c and deoxycytidine
to their respective monophosphates (ara-CMP, dCMP) (44, 79, 104).
In addition, resistance to ara-c is also associated with enhanced
levels of pyrimidine nucleoside deaminase which is the enzyme that
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catalyzes the conversion of ara-c to its Inactive metabolite,
uracil arabinoside (4l, 65).
The importance of deoxycytidine kinase in ara-c metabolism has
pronpted the investigation of the interaction between ara-c and
the enzyme's natural substrate, deoxycytidine.

Since the Km of the

kinase for ara-c is three-fold higher than the Km for deoxycytidine,
the phosphorylation of ara-c is markedly inhibited in the presence
of deoxycytidine (104, 136).

This fact has been invoked to explain

the ability of deoxycytidine to partially rescue ara-c treated cells
(104, 136).

In addition, the phosphorylated products of ara-c and

deoxycytidine (dCTP, ara-CTP) have been reported to be feedback
inhibitors of deoxycytidine kinase (44, 103).

Although ara-CTP

would appear to inhibit its own synthesis, it has, however, only a
weak effect on the enzyme (103).

Also, Skoog and Nordenskjold

reported that the intracellular pool of dCTP following ara-c treat¬
ment is sharply decreased, implying that the inhibition of the kinase
by dCTP does not block the conversion of ara-c to ara-CTP (142).
Since ara-CTP has been shown to be the active form of the drug,
the product of deoxycytidine kinase, ara-CMP, undergoes two additional
phosphorylations which have been reported to be catalyzed by deoxycytidylate kinase and nucleoside diphosphokinase respectively (109,
152).
The subject of the mechanism of action of ara-c is a coup lex
and confusing one.

However, most theories are based on evidence

that this cytidine analog interacts with the DNA synthetic machinery

7

rv.

O'

i>C : -

of the cell.

DNA replication in whole mammalian cells (55, 75,

143), tumor cells (31, 39, 70, 82, 84), and DNA viruses (20) is inhib¬
ited by ara-c.

This body of evidence for DNA synthesis as a target

area for the action of ara-c requires explanation at a more funda¬
mental level.

Three major lines of evidence have been pursued to

approach this: 1) study of the kinetic properties of DNA polymerases;
2) studies of the incorporation of ara-c into nucleic acids; 3)
studies of chromosomal damage, which may represent the morphologic
manifestation of other mechanisms.
As background to the discussion of the specific effects of
ara-c on DNA synthesis, let us briefly characterize the cell's
different DNA polymerase enzymes.

The subject of mammalian DNA

polymerases including the presentation of a standard nomenclature
has recently been reviewed by Bollum (11).
enzymes have been designated:

,

Four distinct mammalian

,/3 2T, and mitochondrial polymerase.

The qc polymerase (maxi polymerase, replicase, polymerase I, and
polymerase A) is a high molecular weight (>130,000) cytoplasmic
piotein and is responsible for the majority of DNA synthesis asso¬
ciated with replication.

Consistent with this role, the enzyme

concentration rises sharply in S-phase (28), it is stimulated by
unwinding proteins and it may be able to use RNA pieces as an initia¬
tor (27).

N-ethylmaleimide is a specific inhibitor of the

poly¬

merase (11).
The/3 polymerase(mini polymerase, polymerase II, polymerase B,
and repair enzyme), is a low molecular weight protein (^45,000)

v.-.

*sn
l/J (A

found in both the cytoplasm and nucleus (26)

Levels of this enzyme

remain constant throughout the cell cycle and it has been presumed to
be involved in post-replication repair (160).

The

polymerase

(R DNA polymerase) accounts for a minor fraction of DNA polymerase
activity (^ 1%) and its role in cellular replication is unknown
(146).

The mitochondrial polymerase also accounts for less than 1

percent of the polymerase activity and function is presumed to be
limited to synthesis of mitochondrial DNA (72, 99).
Most of the research on the interaction of ara-c and DNA poly¬
merases predates the techniques for separating these different en¬
zymes.

Therefore, hypothetical mechanisms of action of ara-c were

based on studies using crude polymerase extracts.
The competitive inhibition of DNA polymerases has been proposed
to explain the cytotoxicity of ara-c.

Many authors have reported

inhibition of crude extracts of DNA polymerases by ara-c.

This in¬

hibition was found to be due to ara-c's competition with deoxycytidine triphosphate (dCTP) as a substrate for DNA polymerases from
partially purified extracts of calf thymus (52, 101) or from Walker
256 Carcinosarcoma (51), with lysates of mouse L cells (55), and
mouse lymphoma cells (106) and with crude reverse transcriptase prepa¬
rations from Raucher Leukemia Virus (106, 154).

The Ki's for ara-c

reported in these studies were reasonably low, suggesting that this cytidine analog might inhibit this reaction within intact cells.

Further

evidence for the competitive nature of this inhibition has been
reported by Furlong (51) who demonstrated that ara-CTP did not inhibit
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incorporation of thymidine triphosphate into DNA synthesized on an
artificial template, poly dA-T.

Since normal rules of base pairing

preclude dCTP incorporation into such a molecule, and ara-CTP did
not block DNA synthesis, it was concluded that ara-c's interference
with polymerase function was limited to competitive binding at the
dCTP site.

The cause and effect relation between the competitive

inhibition of the pofymerase and cell death has not adequately been
demonstrated.
The cytocidal effect of ara-c has been suggested to result from
a state of unbalanced growth caused by inhibition of DNA synthesis
while initially little effect of ara-c on RNA and protein synthesis
occurs (143).

Experiments reported by Graham and Whitmore (55)

attempted to elucidate the connection between cell death and polymerase
inhibition and to refute the theory of unbalanced growth.

Studies

on mouse L-cells showed that 3.6 X lCT^M ara-c inhibited DNA synthesis
by more than 97% and that these cells underwent "unbalanced growth"
for periods greater than one generation (24 hours) without necessarily
losing viability.

However, at a concentration of 7-2 X lCT^M for

2 hours, there was an irreversible loss of viability sufficient to
kill all S-phase cells.

These authors concluded that unbalanced

growth was not responsible for cell death and that if massive inhibi¬
tion of DNA synthesis was to be implicated, a mechanism had to be
proposed whereby preservation of a relatively small amount of DNA
synthesis, as little as 3l of the normal rate, can prevent loss of
viability.

Such a mechanism will be discussed below along with the
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selective effects of ara-c on different cellular DNA polymerases.
There have been numerous reports which apparently contradict
the proposal that competitive DNA polymerase inhibition is causally
related to cell death.

Several investigators (31, 84, 165) have

demonstrated that cell damage induced by high doses of ara-c either
is not reversed or only partially reversed by dCTP.

An irreversible

component of ara-c's action was clearly shown by Karon and Shirakawa
(75).

After Don C cells were treated with 10 jug/ml of ara-c for

24 hours, 80-90% of the cells remained viable as demonstrated by try¬
pan blue exclusion.

However, when these cells were washed and re¬

suspended in drugfree medium, only 10% of the cells were viable by
cloning.

Therefore, despite removal of the drug, ara-c had already

caused an irreversible change.
Momparler's studies on the interaction of ara-c and fluorodeoxyuridine (FUDR) raised yet more doubts as to the role of polymerase
inhibition in cell death (102).

Fifty percent of S-phase HeLa cells

treated with 1 X ICT^m ara-c for 1 hour were killed.

But a subse¬

quent 1 hour treatment with a sublethal dose of FUDR completely
rescued the cells from ara-c toxicity.

Since FUDR is also an S-

phase specific DNA synthesis inhibitor (6l), an additive effect with
ara-c on cell kill and DNA synthesis was anticipated.

Although the

basis for the observed antagonism is unknown, this study further
suggested that cytotoxicity of ara-c is not adequately explained by
inhibition of DNA synthesis.
other investigators (57)*

These results have been confirmed by

In view of the poor correlation of ara-cTs
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cytotoxicity with its competitive inhibition of DNA polymerases,
other known effects of ara-c will be explored in order to further
clarify the subject.
There are several reports that indirectly support the hypothesis
that the acute cytotoxic effect produced by ara-c results from its
incorporation into DNA.

First, H^ara-c has been shown to be incor¬

porated into DNA of various mammalian cells (29, 31, 37, 39, 56,
143, 166).

Second, purified mammalian DNA polymerases can catalyze the

incorporation of H^ara-CTP into DNA in vitro (51, 100, 101).

The

incorporated radioactivity has been chronratographically proven to be
ara-c (31, 37, 166).

Third, short exposures of mammalian cell to

ara-c have been shown to be mutagenic (69).
Despite such evidence that ara-c is incorporated into DNA, the
mechanism of this presumed highly toxic effect needs to be clarified.
One possibility is terminal incorporation of ara-c into DNA with
cessation of chain growth.

This could be a serious lesion and in fact

this chain defect was observed by Momparler using DNA extract from
calf thymus (100, 101).

However, this observation was not confirmed

using DNA polymerase extracts from Walker Carcinosarcoma or in whole
mammalian cells (31, 56).

In both systems ara-c was incorporated

into internal nucleotides exclusively.
The discrepancy between these studies might be explained by the
reported presence in thymus extracts of an unusual DNA polymerase,
terminal transferase (10).

This enzyme, found only in the thymus and

leukemic cells, catalyzes the elongation of preformed oligomeric
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or polymeric DNA chains by adding deoxyribonucleoside monophosphates
to the 3'OH ends of these chains (53).

Terminal transferase is

unlike any other known DNA polymerase in that it does not use nucleic
acid templates for instruction (10).

Therefore, the absence of a free

3'OH group on a strand of DNA results in chain termination since the
polymerase cannot skip to another region of the template and continue
operations.

Consequently, ara-c’s lack of an available 3'OH group

might cause chain termination in the terminal transferase reaction but
not necessarily with other polymerases, which function with a tem¬
plate.

One could speculate that ara-c induced chain termination

in the presence of terminal transferase could be the basis for the
selective toxicity of ara-c for leukemic cells.

Although this hypo¬

thesis is attractive, there are no studies that demonstrate such an
effect; therefore, other lines of evidence must be considered.
One could assume that if the incorporation of ara-c into DNA
represents the cytotoxic lesion, the rate of incorporation would be
proportional to cell lethality.

Such a correlation was not observed

in studies by Graham and Whitmore or Chu (30, 56).

Chu demonstrated

that when murine leukemia L5178Y cells were exposed to 3«3 X lCT^M
ara-c, incorporation of H^ara-c into DNA stopped at 1 hour, although
cell lethality continued to increase.

However, the high dose of ara-c

used could have blocked its own incorporation by inhibiting the poly¬
merase completely.

But, since the higher dose of ara-c is associated

with increased cell death and the incorporation of ara-c into DNA
is dependent on a functional polymerase, for which high dose ara-c

13
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is a potent inhibitor, a new hypothesis would have to be proposed
to reconcile this apparent contradiction.
The discrepancies in the above discussion could be explained
by assuming that the high dose of ara-c potentiates the cytotoxicity
of the ara-c already incorporated into DNA by inhibition of its
excisional repair.

A differential sensitivity to ara-c for the re¬

pair and replicative function of the polymerases was first suggested
by Cleaver (35) s who demonstrated that the repair of ultravioletinduced lesions in HeLa cells containing DNA substituted with 5Bromouracil was not inhibited by ara-c.

There is precedent for this

selectivity of ara-c in other eukaryotic and prokaryotic cells.
In E. coli, three distinct DNA polymerases have been isolated
and designated:

I, II and III (151).

The function of polymerase I

has been implied from studies of E. coli Pol A1 mutant in which this
enzyme is lacking (126).

Since these cells replicated normally

except for increased sensitivity to ulatraviolet-induced damage,
polymerase I has been presumed to be responsible for DNA repair (126).
Polymerase II has been proposed to be the replicase, and consistent
with this function in mammalian cells, its activity is potentiated
by unwinding proteins (126).

Rama Reddy et al. have reported that

the replicase (polymerase II) is sensitive to inhibition by ara-c
while the repair enzyme (polymerase I) is resistant (126).,
finding has been confirmed by others (151).

This

A similar observation

was made by Winterberger in studying the simple eukaryotic organism
yeast (l6l).

The replicase, as In E. coli, was more sensitive to

ara-c than the putative repair enzyme.
14
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The differential sensitivity of various DNA polymerases has also
recently been reported in mammalian cells (45, 90, 91, 137, 149).
Lynch et al. was able to separate two distinct polymerases from iso¬
lated hepatocyte nuclei.

The first was a high molecular weight (7.IS)

protein that showed a marked increase in concentration associated with
the rise in DNA synthesis induced by partial hepatectomy or thyroid hor¬
mone infusion (90, 91).

These properties are consistent with the

mammalian replicase, polymerase °C .

Since the second hepatocyte

polymerase is a low molecular weight (3.2S) protein that is able to
repair single strand breaks in DNA induced by bleomycin (132), it
resembles the mammalian DNA repair enzyme, polymer as q/3 .

Stenstrom

et al. using isolated hepatocyte nuclei were able to demonstrate
that the replicase, polymerase, is 1000-fold more sensitive to
ara-c than is the repair enzyme, polymerase/9 (45, 149).

Lynch

et al. (91) have confirmed these findings using the same system.
However, when normal human lymphocytes were analyzed, the Ki of
polymerase/9
merase csi.

for ara-c was only five-fold lower than that of poly¬

(137).

Although in varying degrees, in all cell lines

investigated to date, the replicase seems to be more sensitive to
ara-c than is the repair DNA polymerase.

Furthermore, this differential

effect suggests a mechanism of action for ara-c which includes both
the previously documented inhibition of DNA synthesis and the incor¬
poration of this analog into DNA.

One could speculate that high levels

of ara-c are necessary to inhibit the repair enzyme which otherwise
would excise the ara-c incorporated into DNA by the replicase.

15
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A possible microscopic correlation of the molecular damage
caused by the cell’s inability to repair incorporated ara-c lesions
is the appearance of chromosomal abnormalities.

Ara-c can produce

marked chromosomal aberration in mammalian cells with chromatid
breaks and extensive fragmentations (5-7, 74, 8l).

Karon et al.

(74) showed that ara-c cytotoxicity correlated very well with the
number of chromosome breaks produced, five or more breaks per metaphase
being lethal to the cell.

The interference of ara-c with chromosomal

integrity as a consequence of inhibition of DNA synthesis and repair
would require that the cytotoxicity of ara-c be limited to cells rap¬
idly incorporating DNA.
Ara-c is a cycle-dependent agent effective only in S-phase,
which is the period of DNA synthesis in the cell cycle (55? 75} 82,
165). This S-phase specificity is due to the inhibitory effect of ara-c
on DNA replication and to an increase in the phosphorylation of ara-c
which results from an S-phase increase in deoxycytidine kinase acti¬
vity (103).

Preceding S-phase is G-^ phase during which the cells

are spared the cytotoxic effects of ara-c.
Several investigators have noticed that ara-c can block the
movement of G-^ cells into S-phase; thus, this drug can be self-limiting
with respect to its cytotoxic activity (1, 55 > 153)-

Although others

have not observed a G-^/S block (76), the observation that ara-c
induced partial cell synchronization strongly supports this effect
(1, 8, 42, 85, 127, 159s 164).

Consequently, cells collected near

the Gj/S boundary could rapidly resume cell cycle traverse as a
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synchronous cohort after ara-c is removed (1, 8, 42, 85, 127, 159, 164).
Other impIdeations of S-phase specificity will presently be discussed.
As it is with DNA, ara-c is also incorporated into RNA (29, 30,
33, 37)*

However, since ara-c causes only minimal impairment of

general cellular RNA synthesis at doses that are inhibitory to DNA
synthesis (36, 55, 108, 165), an effect on a specific RNA might be
obscured.

In fact, when RNA was fractionated, ara-c was not incor¬

porated into high molecular weight rRNA (166) or tRNA (139) but was
predominantly present In low molecular weight mRNA (30).

Further¬

more, Chu (30) has demonstrated that the cytotoxicity of ara-c cor¬
relates

only with this analog's incorporation into low molecular

weight mRNA.

Even though mRNA is synthesized throughout the cell

cycle (120, 155), and even though ara-c is S-phase specific, the
cytotoxicity of ara-c could still result from an interaction with a
specific S-phase mRNA.

One type of S-phase specific protein is

histones, which is a nuclear protein that Is necessary for the assemb¬
ly of the newly-formed DNA complexes (131)-

Histone synthesis requires

a specific S-phase 7-9S mRNA(histone messenger) and Borun et al.
demonstrated selective inhibition of histone messenger and histone
synthesis by ara-c (12, 135).

After treatment with actinomycin D

and ara-c, both histone synthesis and the amount of 7-9S RNA (histone
messenger) associated with polysomes declined four times faster than
after exposure to actinomycin D alone.

Since actinomycin D is known

to block RNA transcription, ara-c's interference must occur after
transcription to account for the rapid decay when synthesis of his¬
tone messenger is no longer occurring.

17

Furthermore, one could

speculate that Incorporation of ara-c into mRNA results In either
accelerated metabolism of mRNA or in interference with translation.
The preceding argument strongly supports the theory that ara-c
incorporation into mRNA Is a mechanism of action of this drug.

How¬

ever, this hypothesis does not mitigate the importance of ara-c’s
inhibition of DNA polymerase or its incorporation into DNA.

All of

the aforementioned modes of action of ara-c could coexist, thereby
explaining the potent cytotoxic nature of this compound.
There is yet another hypothesized locus of action for ara-c
which, however, has been refuted by many investigators.

Initial

studies on the mechanism of ara-c cytotoxicity led to the sugges¬
tion that the drug produced inhibition of DNA synthesis as a consequence
of the inhibition of the reduction of CDP to dCDP by the enzyme ri¬
bonucleotide reductase (31)-

However, when Skoog and Nordenskjold

(142) measured nucleotide pools, ara-c caused only a transient de¬
crease in the dCTP pool.

In addition, when ribonucleotide reductase

was assayed directly, ara-CTP produced a weak inhibition (73, 105),
thereby suggesting that the inhibition of the reductase is not of
significant consequence at the intracellular drug levels usually reached.
Having discussed some of the proposed mechanisms of action of ara-c,
it is important to consider the implications of these theories in the
clinical application of the chemotherapeutic agent.
The clinical efficacy of ara-c as an antineoplastic agent is
profoundly affected by the schedule of administration and dosage of
this agent.

After intravenous injection, ara-c is rapidly deaminated to

18
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ara-u, uracil arabinoside (41).

The plasma half-life for ara-c is

biphasic with an initial fast phase (mean half-life 12 minutes) and
a slower second phase (mean half-time 111 minutes) (65).

In addi¬

tion, Ho and Frei (65) demonstrated that the plasma half-life is
independent of the dose; therefore, higher doses correlated with higher
plasma levels of ara-c.
Since ara-c is S-phase specific and only a small percentage of
tumor cells are in S-phase at a particular time, low dose continuous
infusions have been commonly employed to expose a higher percentage
of cells to ara-c during their vulnerable period (49).

Yet, the

efficacy of intermittent bolus therapy with appropriate dose intervals
has also been demonstrated (110).

The interval required for maximal

cell kill correlates well with the time necessary for recovery of
DNA synthesis following ara-c (110, l4l).

This observation suggests

that ara-c synchronizes cells in early S-phase, and upon recovery
these cells progress to another part of S-phase where they are sensi¬
tive to a second dose of ara-c (85, 110, l4l).

Recalling the pre¬

vious discussion of the dose dependence of the mechanism of action
of ara-c, it is therefore possible that large bolus doses could be
acting at different sites and be as effective as prolonged low dose
infusion.
If the cell kinetics of the tumor cells differ from that of the
host tissues, use of an intermittent dose schedule could improve the
therapeutic index of ara-c by decreasing host toxicity.

For the

treatment of acute leukemia, many clinical protocols employing inter¬
mittent doses or continuous infusions of ara-c have been tested.
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Numerous protocols for the treatment of acute myelogenous leu¬
kemia (AML) have employed ara-c alone or In combination chemotherapy.
Although these protocols differ widely in design, only the outcome of
the most promising ones will be discussed as a standard of comparison
for proposed new combinations.

When used as a single agent for the

treatment of adults with AML, ara-c has induced complete remission
in approximately 25 percent of the patients (9, 5*0-

A remission

rate of 65 percent has been achieved by the combination of ara-c and
thioguanine given every 12 hours until marrow hypoplasia resulted
(34).

In addition, the combination of a four-day course of daily

ara-c with daunorubicin on day 1 induces complete remission in over
50 percent of patients with AML (110).

A greater than 50 percent

remission rate was also achieved with a complicated protocol involving
ara-c, vincristine, prednisone and cyclophosphamide (150).
Ara-c has also been tried in the treatment of acute lymphocytic
leukemia (ALL).

However, since only one-third of patients with

ALL achieved either a complete or partial remission with ara-c (144)
and other agents are significantly more effective, the use of ara-c
in ALL is limited to patients resistant to standard therapy.

L-Asparaginase
Since the original discovery of a tumor inhibitory factor in
guinea pig serum by Kidd (64) and its identification as asparaginase
by Broome (16), this enzyme has been shown to be tumoricidal to
selected rodent (16, 80), canine (64;, 113) and human (66) neoplasms.
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Although asparaginase has been isolated from a wide variety of sources,
the bacterial enzyme from E. coli is most often used clinically and
for investigation (15, 116).
E. coli asparaginase (EC-2) is a 127,000 molecular weight protein
that catalyzes the hydrolysis of asparagine to aspartic acid and
ammonia (15, 17, 24, 37, 66, 95).

In addition, as an inherent property

of the enzyme, it has a small amount of glutaminase activity, which
catalyzes the conversion of glutamine to glutamic acid and ammonia
(116).

Following the perenteral administration of asparaginase,

plasma asparagine rapidly falls to undetectable levels (17, 24, 37,
66, 95, 130) and there is also a delayed transient decrease in glutamine
(116).
The consequences of asparagine deprivation are the result of
its important role in cellular function.

The major metabolic use

of asparagine is as one of the required animo acid constituents of
proteins (24, 47, 95, 96, 147, 163).

However, since most cells are

capable of de novo biosynthesis of asparagine by the enzyme asparagine
synthetase (16, 66, 122), asparagine is not an essential nutrient
for mammalian cells (16, 17, 24, 116).

In 1956, however, Neuman

and McCoy (111) demonstrated for the first time a cell line. Walker
Carcinosarcoma 256, which in contrast to normal mammalian cells has
a nutritional requirement for asparagine.

This finding has since been

confirmed and extended to a limited group of tumor cells (15-17,
24, 58, 66, 92, 96).

In fact, tumor cells that require exogenous

asparagine as expected have either low or absent levels of asparagine
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synthetase (17, 62, 119, 122).

Furthermore, cells that require

asparagine are susceptible to the lethal effects of asparaginase
(17, 62, 66, 118, 119, 122) and the development of asparaginase
resistance is associated with increased levels of asparagine syn¬
thetase (17, 62, 66, 118, 119, 122).

Therefore, one can conclude

that the antitumor action of asparaginase is the result of asparagine
depletion (17, 62, 66, 118, 119, 122).
Although the mechanism of cell death following asparagine de¬
pletion has yet to be fully elucidated, the inhibition of protein
synthesis following asparagine depletion or asparaginase has been
well documented (24, 47, 89, 95, 96, 138, 147, 148, 163).

One class

of proteins that has a high asparagine content is glycoproteins
(77)*

The high asparagine content of these proteins is very sig¬

nificant in that the oligosaccharide chains are covalently bonded to
asparagine residues (24).

Since cell membranes have a high glycopro¬

tein turnover (14), and asparaginase inhibits glycoprotein synthesis
(59, 71, 77),

treatment with asparaginase could result in loss of

membrane integrity (13, 14, 77, 78).

Furthermore, such membrane

damage would account for the observed rapid lysis of susceptible
cells following asparaginase (43, 67).

An alternate explanation of

cell l^sis has also been proposed by Dod et al. (43) who showed that
asparaginase could directly solubilize partially purified cell membranes
in vitro.
Aside from inhibition of glycoprotein synthesis, there are other
important disruptings in cellular mechanisms induced by asparaginase.

22

--

\lj

Following the rapid inhibition of protein synthesis, there is a
delayed inhibition of DNA (24, 47, 66, 89, 96, 148) and RNA (24,
47, 66, 89, 96, 148) synthesis.

The delay suggests that the decrease

in DNA and RNA synthesis is secondary to the inhibition of protein
synthesis (47, 66, 96, 148).
The initiation of DNA synthesis requires the synthesis of special
proteins (63, 121, 140).

The inhibition of protein synthesis in late

Gq phase results in the inhibition of the initiation of DNA synthesis
and hence blocks the transition of cells into S-phase (50, 68, 117).
Asparaginase, as an inhibitor of protein synthesis, would thus be
expected to block the initiation of DNA synthesis, resulting in an
accumulation of cells at the G^/S junction.

In fact, an asparaginase-

induced G-j/S block of cell cycle traverse has been reported by several
investigators (86, 117, 136).

However, a contradictory result was

observed by Ernest (48), who demonstrated that asparaginase inhibited
S-phase cells but did not block the G-^ to S transition.

Finally,

Paliardi et al. (115) were also unable to confirm an arrest of cell
passage from G^ to S-phase.

Albeit that the effect of asparaginase

on the cell cycle is controversial, most investigators feel that this
effect is of secondary importance in contrast to the previously dis¬
cussed independent lytic effect (48, 117).
Other hypotheses for the mechanism of action of asparaginase,
Welch are independent of its effect on protein synthesis, have been
described.

Wood et al. (162, 163) have proposed that asparagine,

depletion, and therefore asparaginase, has a direct Inhibitory effect
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on DNA synthesis by blocking de novo biosynthesis of pyrimidines.
They demonstrated that C

asparagine is incorporated into pyrimidines,

suggesting a role for asparagine as a precursor for pyrimidine syn¬
thesis.

Even though asparagine is not directly involved in pyrimi¬

dine synthesis (88), its conversion to a required precursor such as
glycine could explain the incorporation of label into pyrimidines.
Meister (98) has described just such a pathway for glycine synthesis
from asparagine.

Moreover, if asparaginase inhibits glycine synthesis,

the effects of asparaginase should be able to be blocked by the
administration of exogenous glycine.

In fact, not only can glycine

antagonize the effect of asparaginase (130)

but plasma levels of

glycine fall following treatment with asparagine (129), further
supporting the requirement of asparagine in glycine and nucleotide
synthesis.

However, significant decreases in intracellular pyrimidine

pools following asparaginase have yet to be demonstrated and therefore,
the importance of asparaginase inhibition of pyrimidine metabolism
and DNA synthesis cannot now be determined.
Another site of action for asparaginase might involve the enzyme
ribonuclease.

An increase in ribonuclease, an enzyme that hydrolyzes

RNA, has been proposed as a causal agent in the regression of murine
lymphosarcoma P1798 (2) since only tumoricidal drugs including aspara¬
ginase caused this increase (2, 94, 97)-

Although this does not suggest

a specific mechanism of action of this drug, it provides evidence that
asparaginase may share a common final pathway with other agents in
the induction of lymphocytolysis.
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Although 15 years have passed

since Broome (16) identified asparaginase as the cytotoxic component
of Guinea Pig Serum, the exact tumoricidal mechanism of this enzyme
is still unknown.

However, this has not prevented the successful

clinical application of asparaginase in the treatment of acute leukemia.
The clinical efficacy of asparaginase is almost entirely limited
to the treatment of acute leukemia (24).

Oettgen (112) has recently

reviewed the clinical results of asparaginase therapy, alone and in
combination with other drugs.

The best responses to asparaginase therapy

were in children and adults with acute lymphocytic leukemia.

Of

the 395 patients reviewed who were treated with asparaginase alone,
214 achieved either a complete or partial remission (54%) (112).
However, of the 200 patients with acute nonlymphocytic leukemia,
including acute myelogenous, acute myelomonocytic and acute undiffer¬
entiated, only 21% had either complete or partial remissions with
asparaginase therapy alone (112).

Asparaginase in Combination Chemotherapy

Although the use of several combinations of asparaginase with
other cytotoxic agents have been reported to be synergistic in animals
and/or man, only the combinations of asparaginase with ara-c or metho¬
trexate will be discussed here because of their direct importance
to this thesis.

Since ara-c and asparaginase are both useful drugs

in the treatment of acute leukemia, and since they have different
host toxicities (9, 54, 112), their combination is a logical choice.
In fact, the combination of ara-c and asparaginase has been shown to
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be more effective than either drug alone in the treatment of human
and murine leukemias (4, 19, 46, 60, 87, 114, 124, 125).

Although

several trials have employed this combination in the therapy of acute
lymphocytic leukemia (46, 60, 114, 125), there are no reports to my
knowledge of such a trial in acute myelogenous leukemia.
The first clinical trial of the combination of ara-c and aspara¬
ginase was conducted by Hardisty and McElwain (60) who reported 8
complete remissions in 9 children with previously treated acute
lymphocytic leukemia.

The protocol consisted of using ara-c daily

for 5-14 days followed by daily asparaginase for 9-28 days.

The

value of the sequential administration of ara-c, then asparaginase,
was confirmed by Ekert et al. (46).

They reported 8l% complete or

partial remission in 17 children with acute lymphocytic leukemia,
using an ara-c bolus every 8 hours for 4 days followed by 4 daily
doses of asparaginase.

Finally, sequential administration of ara-c-

asparaginase was also shown to be synergistic in murine leukemia
EARAD (19).

In contrast, simultaneous treatment with both ara-c

and asparaginase has been reported to produce in acute lymphocytic
leukemia remissions rates of 6l% (15/24) and 68% (15/22) in two
separate studies (114, 125).

Simultaneous exposure in mice produced

a synergistic response in the treatment of murine L5178Y when both
drugs were administered in large doses on each of three separate
days (4).

Although all the reported protocols for the combination

of ara-c-asparaginase resulted In an enhanced response rate as compared
with asparaginase alone, the optimal schedule for the administration
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of this combination has not yet been determined, but it is inves¬
tigated further in this thesis.
For the treatment of murine and human leukemias, the importance
of the schedule of administration of asparaginase with another Sphase specific DNA synthesis inhibitor, methotrexate, was first demons¬
trated by Capizzi et al. (22, 23, 25).

They noticed that when mice

with murine leukemia L5178Y were treated with asparaginase preceding
methotrexate by less than 24 hours, there was an antagonistic response
in mean animal survival time.

However, when the order to the drugs

was reversed and methotrexate preceded asparaginase, this antagonism
was not observed.

Furthermore, the subsequent treatment with as¬

paraginase also decreased methotrexate’s host toxicity and since
the tumoricidal effect was not diminished, this regimen resulted
in an enhanced therapeutic index.

These results have been confirmed

by other investigators (83, 156, 157).
Since ara-c and methotrexate are both S-phase specific inhibitors
of DNA synthesis, their similarity suggested that their interaction
with the protein synthesis inhibitor, asparaginase, might be similar.
Therefore, the studies of Capizzi et al. (22, 23, 25) on the combina¬
tion of methotrexate and asparaginase served as a basis for investigating
whether the combination of ara-c-asparaginase also showed scheduledependency.

The purpose of this thesis is to determine the optimal

schedule for the administration of ara-c and asparaginase and to
attempt to clarify the biochemical basis of the interactions observed.
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Methods

Leukemic Cell Lines

All animal and tissue culture studies were performed with the
L5178Y/asn“ murine leukemic cell line. These cells require asparagine
for growth and therefore are sensitive to asparaginase (4, 58, 134).
In addition, these cells are also sensitive to ara-c in vivo and in
vitro (4, 32, 33).
Stock lines of L5178Y were maintained in vivo as an ascites tumor
in 20-25 gram female
Me.).

mice (Jackson Laboratories, Bar Harbor,

The tumor was transferred at weekly intervals into new mice

by intraperitoneal injection of 10^ cells.

For in vitro studies,

stock lines of L5178Y were maintained as liquid suspension culture in
Fisher’s medium supplemented with 10$ horse serum (designated FS^
and purchased from Grand Island Biological, New York) and were kept
in continuous logarithmic growth by frequent subculturing.

Fisher's

medium was protected from light by wrapping the bottles in aluminum
foil in order to prevent the formation of toxic photoxidation products
(3, 150).

All cultures were maintained at 37° C, in a 5% CO^ incu¬

bator and under these conditions, these cells had a mean doubling time
of 8.5 hours.

In Vivo Tumor Growth Curves

Mice were inoculated intraperitoneally with 10^ L5178Y ascites
28
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tumor cells in a volume of 0.1 ml diluted in sterile normal saline
(NSS).

On day 3, animals were treated with either ara-c 1000 mg/kg

(Upjohn, Kalamazoo, Mich.), asparaginase 500 IU/kg (Merck, Sharp and
Dome, Pa.) or normal saline.

The drugs were freshly prepared from

sterile powder in normal saline and the final injection volume was
0.1 ml.

At various intervals, two animals were sacrificed by cervical

dislocation.

The skin over the peritoneum was opened and the peri¬

toneal cavity was lavaged with three 5 ml aliquots of heparinized
normal saline (0.5 IU/ml) to collect the tumor cells.

After dilution with

NSS and the addition of 3 drops of Zapisoton (Coulter Electronics,
Hialeah, Fla.) to lyse the red cells, the tumor cells were counted in
a Model A Coulter counter (Coulter Electronics, Hialeah, Fla.
Tnis counter was used for all experiments in this thesis).

Results

were expressed as total cells per animal.

Animal Survival Studies

Six groups of 6 mice were segregated into separate cages and
oJ

inoculted with tumor and treated with drugs that were prepared as

A

described above.

The treatment schedule is described in Table 1.

As an indication of drug toxicity, each group of animals was weighed
daily until they regained their pretreatment weight and there were no
deaths due to drug toxicity in any of these studies.

Results were

expressed as mean animal survival in days following tumor injection
and 60 day survivors were considered cured.
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In Vitro Cell Viability

Thirty-five ml of L5178Y cells in log phase growth at a concentration of 1-3 X 10

5

cells/ml were treated with 1 ml of a drug freshly

prepared in NSS according to the treatment schedule in Table 2.

Pre-

and post-treatment cell counts were determined in a Model A Coulter
Counter after a 1:10 dilution with NSS.

Following an 8-hour drug

exposure, the cells were washed three times by centrifuging them for
10 minutes at 1000 rpm in a Sorvall GLC-2 centrifuge (Dupont Indus¬
tries, Newtown, Conn.) in a 37° room and then resuspending the cells in
35 ml of drug-free FS^ by gentle pipetting.

One hour and thirty

minutes after concluding the first centrifugation, the cells were
treated a second time as diagrammed in Table 2.

At the conclusion

of a second 8-hour exposure, the cells were again counted and washed
as above and viability was determined by a slight modification of
the soft agar cloning technique described by Fisher and Chu (32).
In contrast to the 60 cells/tube used by Fisher and Chu, the inoculum
used in these experiments was either 100 and/or 200 cells per tube
depending upon the anticipated cell kill.

Cloning efficiency varied,

the mean being 75% and the data was therefore normalized and expressed
as percent of control cloning efficiency.
A sequence of experiments was undertaken to determine if the 1
hour and 30 minutes between treatments was critical.

The four time

intervals tested were as follows:

b) 1 hour

thirty minutes

c) 4 hours

a) 1 hour overlap

d) 8 hours.

In group A the second drug

was added 1 hour prior to the conclusion of the first treatment and
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was therefore included in the FS-^q used in washing.

The treatment

schedule is diagrammed in Table 3-

In Vitro Growth Curve Following Ara-c Pretreatment

L5178Y cells in culture were treated with either ara-c (final
concentration 10~^ M) or normal saline for

8h

hours as described

above for the first treatment of the in vitro viability studies.
Following the resuspension of the cells after the third wash, hourly
cell counts in duplicate were measured by diluting 1 ml of cells with
9 ml of NSS.

Prior to counting, the diluted cell suspensions were dis¬

persed with a pasteur pipette.

A graph of cell concentration as a

function of time post-wash was used to express these results.

Incorporation of TdR into DNA

L5178Y cells in culture were pretreated as described above for
the in vitro growth curve.

Following the third wash the cells were

resuspended in FS-^q to a final concentration of 3-6 X 10

cells/ml.

One ml of cell suspension was then placed in a sterile, stopperred,
10 ml Erlenmeyer flask that already contained either 0.1 ml of normal
saline solution or 0.1 ml of asparaginase (6 IU/ml prepared in NSS).
Following a 1 hour preincubation at 37° C in a Metabolyte shaking
water bath (New Brunswick Scientific Company, New Brunswick, N.J.),
0.1 ml of H
medium.

deoxythymidine (1 uc of H

methyl TdR diluted in Fisher's

Specific activity 2.0 C/rrM from New England Nuclear, Boston,

Ma.) was added to the incubation mixture.
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for the next 1 hour, 0.1 ml of the mixture was removed and applied to
a glass fiber disc (2.4 cm GF/A Whatman filter) which had been pre¬
treated with 0.2 ml of 0.5 M NaOH and allowed to dry.

At the conclu¬

sion of the incubation, the discs were dried under a heat lamp and placed
on Whatman #1 filter paper in an 18 cm Buchner funnel mounted on a
suction flask.

Up to three layers of discs, separated by Whatman #1

filters were washed with ten 100 ml aliquots of ice cold 5% trichloro¬
acetic acid (TCA) followed by four 100 ml aliquots of 95% ethanol
and then four 100 ml aliquots of acetone.

The discs were again dried

and then transferred to scintillation vials with 10 ml of Econofluor
(New England Nuclear, Boston, Ma.).

The samples were counted in a

Packard Tricarb Liquid Scintillation Counter (Packard Electronics).
The rate of incorporation of H

TdR into DM was calculated using

linear regression analysis and the results were expressed as dpm/10^
cells/minute of incubation.
An alteration of this general method was used when it was desirable
to determine DM synthesis within 1 hour post-ara-c treatment.

For

these experiments, the cells were divided into two groups, half was
washed with FS1Q plus asparaginase (0.5 IU/ml) and the other group with¬
out asparaginase.

Also to accomplish the removal of the drug within 1

hour, the washing was reduced to three 7 minute centrifugations.
At 1 hour 1 ml of cells was placed in a 10 ml flask and 0.1 ml of H
TdR was immediately added since the 1 hour wash with asparaginase
was approximately equivalent to preincubating with the drug for
1 hour.
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Ara-c Incorporation Into Macromolecules
TWo ml of 1-2 X 10 ^ L5178Y cells in FS10 were added to a 10 ml

sterile, stopperred ErTenmeyer flask that contained 0.2 ml of H
ara-c (5 uc of specific activity 13-2 mc/nM.

Prepared in Fisher’s

medium and purchased from New England Nuclear, Boston, Ma.).

In

order to determine if asparaginase inhibited ara-c's incorporation into
DNA and/or RNA, six flasks of cells were treated as follows:

two of the

flasks received 0.1 ml asparaginase (12 IU/ml) initially, two others
received 0.1 ml of asparaginase (12 IU/ml) after 2 hours and the re¬
maining two flasks received 0.1 ml of normal saline.

Every thirty

minutes for 4 hours, 0.2 ml of the mixture was removed and spotted
on glass fiber discs that were previously treated with both 0.2 ml of
0.5 M NaOH and 0.2 ml 10

-4

M cold ara-c.

The discs were then washed

and counted as described above for TdR.

H

Leucine Incorporation into Protein

Cells were prepared as previously described for TdR but received
0.1 ml H

2

Leucine (2 uC of 4,5H

2

leucine specific activity 5 C/mM

purchased from New England Nuclear, Boston, Ma.).

The 0.1 ml aliquots

were pipetted into 3 nil of ice cold 10% Trichloroacetic acid and the
samples were processed and counted by the method described by Rosenfelt

(128).
Autoradiography and Mitotic Index

One ml of 2 X 10^ L5178Y cells was placed in a stopperred, sterile,
10 ml Erlenmeyer flask with 0.1 ml
33
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New England Nuclear, Boston, Ma.) and 0.1 ml colcemid (final concen¬
tration 0.05 ug/ml from Grand Island Biological, New York).

At the

conclusion of a 1 hour Incubation, the cells were washed two separate
times with 3 nil of cold normal saline and then resuspended in 2 drops
of horse serum.

After the slides were prepared and dried, they were

fixed for 15 minutes in absolute methanol.

The slides were developed

by the method of Durie and Solomon (18) with the exception that after
dipping them in the emulsion they were not redipped into scintillation
fluid and consequently exposure time was increased to 4 days.

The

autoradiograms were stained with Geimsa and Wright stain and 500 cells
on duplicated slides were counted to determine the mitotic and labeling
index.
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Results and Discussion

The design of a chemotherapeutic protocol for the use of aspara¬
ginase plus ara-c should be guided by the pharmacology of the individual
agents as reviewed above.

Although it is inpossible to predict a

priori the interactions that will occur, an initial hypothesis can
be based on known cytokinetic effects.

Since ara-c is an S-phase

specific agent (55, 75, 82, 165) which is therefore most effective
against rapidly dividing cells, an additive or synergistic response
might be expected to occur if cells were treated with ara-c shortly
after they were released from the inhibition of asparaginase which
has been reported to cause a G^/S block (86, 117, 133)-

To explore

this hypothesis, a preliminary group of experiments was necessary
to determine when L5178Y cells recover from asparaginase toxicity
in vivo.

Therefore, a tumor growth curve in mice following aspara¬

ginase was determined as described above.
experiments is presented in Figure 1.

The pooled data of two

After a single injection of

asparaginase, there is a greater than one log cell kill followed by a
plateau of cell number for 4 days.

Between 120 and 144 hours post¬

treatment, the remaining tumor cells resume logarithmic growth.

A

similar observation has been previously reported by Rosenfelt (128).
Consequently, one of the treatment regimens tested in mice was the
administration of asparaginase on day 3 post-inoculation with tumor and
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MOUSE
/
CELLS
ASCITES
Figure 1:Effects of 500 IUAg of Asparaginase upon the total number
of ascites cells per mouse. Data points represent the pooled re¬
sults of two experiments.
( )=number of animals per time point
and the point is the mean of those animals.
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then 120 hours later a single bolus of ara-c was administered.
Another Initial hypothesis was based on a presumed asparaginaseinduced G./S block (86, 117, 133) which has been suggested to result
from the inability of the cell to initiate DNA synthesis in the absence
of protein synthesis (63, 121, 140).

In addition, recovery from the

DNA synthesis inhibitor, ara-c, probably requires de novo synthesis of
certain proteins.

Therefore, it might be optimal to treat cells

with asparaginase just prior to their resumption of DNA synthesis
while in the process of recovering from ara-c.

Under these conditions,

asparaginase might block cells from recovering from ara-c’s toxicity.
To determine the appropriate treatment interval, an in vivo tumor
growth curve following ara-c was determined as described above and is
presented in Figure 2.

This growth curve implies that the cell number

increases rapidly after 144 hours and it is thus likely that most re¬
maining cells begin to recover approximately 120 hours after ara-c.
Therefore, in the design of a trial treatment schedule, asparaginase
followed ara-c by 120 hours.
Finally, the third schedule of the combination of ara-c and
asparaginase tested was the simultaneous treatment with both drugs on
day 3-

This was selected because it has been reported to be clinically

useful (114, 125) and also to serve as a control for the other pro¬
tocols .
The treatment schedules and results of the animal survival studies
are presented in Table 1.

Treatment with ara-c alone prolonged the

life of all mice and cured 3 of 24.
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Furthermore, treatment with
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Figure 2: Effect of 1000 mgAg of ara-c upon the total number of
ascites cells per mouse. Data points represent the results of
one experiments. ( )=number of animals per time point and the
point is the mean of those animals.

Table I
Effect of different treatment schedules on mean survival time and
the number of animals cured following IP injection of 10° tumor
cells on day 0. All drugs delivered in 0.1 ml. Asparaginase= 500
IU/kg. Ara-c = 1000 mg/kg. The results are expressed as Mean
Survival + standard deviation and represent the pooled data from
Cure= 60 day survivors.
4 experiments.
Group

Treatment
Day 3

Day 8

Mean Survival
(Days)

Cured/Total Animals

I

Saline

10.1 + 1.7

0/46

II

AsnT ase

2.6.4 + 1.8

0/34

III

Ara-C

21.0 + 2.7

3/24

IV

Asn’ase
Ara-c

18.1 + 1.8

1/24

V

Asn’ ase

Ara-C

21.9 + 4.3

1/24

VI

Ara-C

Asn' ase

30.3 + 0.9

20/24

+
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asparaginase alone cured none of the animals and although it prolonged
the life of all animals, asparaginase was slightly less effective than
ara-c alone.

When animals were treated simultaneously with both drugs

or when asparaginase preceded ara-c by 120 hours, animal survival was
equivalent to ara-c alone.

However, when ara-c preceded asparaginase by

120 hours, there was a marked synergistic response with 83% (20/2*1)
of the animals being cured.

In addition, there were no toxic deaths

and the maximum weight loss in any group was 10%.

These experiments

demonstrate a schedule-dependent synergistic protocol for the treat¬
ment of mice carrying L5178Y leukemia and this protocol has minimal
host toxicity as measured by weight loss.
The effect of the combination of ara-c and asparaginase on animal
tumor models has been reported by other investigators (4, 19).

In

contrast to the results of this study, Avery and Roberts observed
that the simultaneous treatment of L5178Y bearing mice with these two
drugs on each of three days (day 1, 4, and 7) cured 36 of 43 mice
(146).

Furthermore, three doses of ara-c alone cured none of the an¬

imals, and three doses of asparaginase cured only 3 of 15 mice.

Even

though the drug doses used by Avery and Roberts for each injection were
similar to those employed in this study, their use of multiple doses
and short intervals between doses complicates the comparison of these
two experiments.

In addition, based on the studies of Avery and

Roberts it is difficult to separate the interaction of the simul¬
taneous administration of both agents from the effects of either
drug with a subsequent dose.

In fact, the synergism observed by Avery

and Roberts may actually support the advantage of the sequential
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administration of ara-c and then asparaginase if as a consequence
of multiple doses, asparaginase is enhancing the effect of a previous
dose of ara-c.

The superiority of the sequential regimen is further

supported by an animal survival equivalent to that reported by Avery
and Roberts for the studies reported here despite a larger tumor
burden at the time of initiating therapy.

The animals used here had

a larger tumor burden since treatment was initiated on day 3 in con¬
trast to the mice used by Avery and Roberts which began receiving
therapy on day 1.

The delay of therapy to day 3 results in the mice

having at least one log more cells than on day 1, thereby increasing
the difficulty of curing the animals (158).
A synergistic increase in animal survival for the combined use
of ara-c and asparaginase in treating murine leukemia EARAD-^ has also
been reported by Burchenal (19).

In that study, 7 of 10 mice were

cured with ara-c 10 mg/kg on days 3-7 followed by asparaginase 500 RJ/kg
on day 7-

In addition, a direct comparison between the studies of

Berchenal and those reported here is complicated by different animal tumor
model, dosage schedules for ara-c, and intervals betewen ara-c and
asparaginase.

However, analysis of these two studies raises the

possibility that the 120 hours interval between ara-c and asparaginase
used in this project may not be critical and that further studies
are needed to define the precise schedule dependency of this combination.
In view of the efficacy of the sequential administration of
ara-c, then asparaginase in vivo as described above, experiments
were conducted in cell culture to define the nature of the drug-drug
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interaction devoid, of host-mediated effects.

Prior to investigating

the effects of the combination on cell viability, it was necessary,
as before, to determine when the cells begin to recover from ara-c
toxicity.

Therefore, an in vitro growth curve as described under

Methods was done.

A typical growth curve is presented in Figure 3 and

it shows that following a 2-hour lag, the ara-c pretreated cells begin
to rapidly increase in number.

In fact, the shorter doubling time

for the midpoint of the ara-c curve (6.8 hours) as compared to the
control (11.0), suggests that ara-c pretreatment may have partially
synchronized the cells.

The synchronization with ara-c will be dis¬

cussed in detail below.
Data derived from the in vitro growth curve implied that cells
resume active growth 2 hours after ara-c’s removal.

Therefore, if

asparaginase treatment was to precede the recovery of cells from ara-c,
the addition of asparaginase would have to be within 2 hours of drug
removal.

Since 90 minutes is the minimum time for washing a large

number of samples, this was selected as the time interval between
treatments in the cell viability studies.

The treatment schedule and

results of these experiments are presented in Table 2.

At a concen¬

tration of 10"6 M, ara-c was moderately toxic with a mean viability of
52.8%.

The dose of asparaginase chosen (0.5 IU/ml), however, was more

lethal and the mean viability was only 23%.

The evaluation of the com¬

bination requires an understanding of the anticipated response.

For

in vitro cell viability studies, an additive response is defined
as the product of the percent viability of the two single drugs and
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Figure 3: Outgrowth of L5178Y cells in culture following
8 hours of treatment with either normal saline( t ) or
ara-c ( X ).
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a response with greater cell kill is considered synergistic (158).
Using this definition, an additive response for ara-c plus aspara¬
ginase would be expected to result in a 13$ viability.

The 7$ via¬

bility observed for the sequential treatment with ara-c and then
asparaginase is at least additive if not synergistic.

However, the

simultaneous addition of both drugs (22.8$) was no more effective
than asparaginase alone (23.0$).

Furthermore, when asparaginase pre¬

ceded ara-c (50.3$) an antagonistic response occurred with the com¬
bination being significantly less effective than asparaginase alone
(p >.005).

These results support the schedule-dependent synergy and

antagonism observed in vivo.
To determine if the 90 minute interval between treatments was
critical, two experiments were performed using the protocol

outlined

in Table III and the normalized results are also presented in Table IV.
Figure 4

is a graphic representation of the means of both experiments

expressed as a percentage of the anticipated additive response for both
drugs versus the time post-wash.

This graph shows that the synergis¬

tic response observed when ara-c precedes asparaginase is lost when the
interval between treatments exceeds 90 minutes.

In conjunction with

the data from the growth curve, this result implies that for aspara¬
ginase to be effective, the cells must be treated prior to their re¬
sumption of active growth following ara-c.
The curve for treatment group 5 (asparaginase preceding ara-c)
in Figure 4 suggests that the longer the interval between the two
drugs the greater the degree of antagonism.
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At first analysis, it

Table II

Effect of different treatment schedules on cell viability in vitro
Ara-c=10”°M. Asn'ase=asparaginase 0.5 IU/ml. Viability expressed
as a percentage of control + one standard deviation.
Protocol

I Treatment 11 Wash I Treatment 21 Wash
'S hours
'90 min.
8 hours

Viability

No. Exp.

I

Saline

Saline

II

Saline

Ara-C

52.8 + 19.3

10

III

Saline

Asn' ase

23.0 + 11.1

10

IV

Ara-C

Asn' ase

V

Asn' ase

Ara-c

50.3 + 17.4

4

VI

Saline

Ara-c plus
Asn' ase

22.8 +

9

100

7.0 +

Statistical Significance (Student's T test)
II
II
II
III
III
III
V

vs
vs
vs
vs
vs
vs
vs

IV
V
VI
IV
V
VI
IV

P

.001
NS

P
P
P
NS
P

.005
.025
.005
.001

NS=not significant

4.0

5.7

4

. -X'f

'•

Table III
The Effects of the Treatment Interval on Cell Viability in Vitro
Treatment 1

Treatment 2

I

Saline

Saline

II

Saline

Ara-c

III

Saline

Asparaginase

Ara-c

Asparaginase

Asparaginase

Ara-c

Saline

Ara-c plus Asparaginase

Group

IV
V
VI

t

TREATMENT 1

*

n
o Hours

TREATMENT INTERVALS
Begin Wash
TREATMENT 2

1 —A

i

1

I

8 hr.

B

1

s
90 min.

8 hr.
[
8 hr.

4 hr.
8 hr.

1

8 hr.

Interval

Group

A - 1 hr. overlap

I
II
III
IV
V
VI

B - 90 min.

I
II
III
IV
V
VI

100
54
30
13
53
30

100
64
22
5
72
14

C - 4 hours

I
II
III
IV
V
VI

100
56
33
36
50
24

100
46
10

I
II
III
IV
V
VI

100
24
17
17
38
23

100
58
10
14
57

D - 8 hours

Viability (%> of Control)
EXP 1
EXP 2
100
100
72
87
44
30
12
10
68
71
28
24

18
42
15

28

RESPONSE
ADDITIVE
ANTICIPATED
OF
PERCENTAGE

Figure 4: Effect of the treatment interval on cell viability as a
percentage of the expected response (as explained in text) following
treatment with both ara-c and asparaginase. The line at 330%
is equal to the effect of asparaginase alone as a percentage of the
anticipated additive response. Data points=average of two experiments.
4
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appears that ara-c is actually rescuing cells Prom asparaginase toxicity.
However, an alternate explanation can be derived from the pre- and
post-wash cell counts.

In contrast to ara-c, when cells are washed

following this dose of asparaginase, there is a mean cell loss of 75%
as compared with the pretreatment cell number.

This implies that

the cytotoxicity of asparaginase is underestimated by the cell viability
since there is a large degree of lymphocytolysis.

Cell lysis following

asparaginase has been previously reported (136, 139)-

The longer

the interval post-asparaginase the greater the number of cells that can
express the lytic affect of asparaginase toxicity.

Therefore, since

cloning only represents the viability of intact cells, the apparent
antagonism of this combination at treatment intervals of 4 or 8 hours
may be only artifactual because asparaginase's toxicity is under¬
estimated.
The data presented above strongly supports the superiority of
the sequential administration of ara-c and asparaginase.

One possible

explanation for the efficacy of this drug regimen is that ara-c pre¬
treatment potentiates the effect of asparaginase on macromolecular
synthesis.

To explore this hypothesis, the effect of asparaginase on

the rate of DNA. synthesis as measured by TdR incorporation in cell cul¬
ture following ara-c treatment was determined as described above and
the results are summarized in Table IV.

Contrary to the above hypo¬

thesis, both the ara-c pretreated and the control group had approximately
a 60% inhibition of DM synthesis following 1 hour preincubation with
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Table IV
Effect of
beginning
saline or
deviation

3

Asparaginase on H TdR incorporation 210 minutes after
washing following 8 hour pretreatment with either
ara-c 10“°M. Data represents the mean and standard
of 6 experiments. Rate=dpm/10b cells/minute incubation.

Protocol

Rate

Control

15220 + 3618

Control + Asparaginase

5925

Ara-c

21390 + 4685

Ara-c + Asparaginase

^Control

+

% Inhibition

61.1%

893
V\l%

57.8%

9075 + 1153

Table V
Effect of Asparaginase on H^TdR incorporation 210 minutes after
beginning washing following 8 hour pretreatment with either saline,
ara-c 5 X 10-6m or ara-c 5 X 10“7m. Data represents the mean of
two experiments. Asparaginase=0.5 IU/ml as described in text.
Rate=dpm/10b cells/minute of incubation. Control is the same as
in Table IV.
Protocol
Control

Rate

5925

Ara-C (5 X 10"6M)

8888

Ar£HC (5 XAS’parSginase)

% Inhibition

15220

Control + Asparaginase

Ara-c (5 XA10"6M +
Asparaginase %
Ara-c (5 X 10-7M. )
;

% Control

61.U6
41.6/6
50. 8$

4375
16353
8062

107$
50.7%
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asparaginase.

Furthermore, In order to exclude the possibility

that the degree of inhibition with asparaginase might be a function
of the concentration of ara-c used, the results of three different
dosages (5 X 10-^, 1 X 10-^ and 5 X 10“^) were determined and are
summarized in Table V and the variation in inhibition ranging from

50 to 58 percent is probably not significant.
Finally, studies were undertaken to determine if the percentage
inhibition of DNA synthesis induced by asparaginase was constant
at different times post-wash.
A/I and Figures 5} 6.

These results are presented in Table

As expected. Figure 5 demonstrates a constant

rate of DNA synthesis for the control.

However, following ara-c's

removal DNA synthesis is initially inhibited but at 210 minutes,
it reaches a peak of lHl% of control.

This curve suggests S-phase

synchronization and will be discussed in detail below.

Figure 6

shows that although both the rate of DNA synthesis and the percentage
inhibition with asparaginase is constant for the control, following ara-c
pretreatment, there is variation in both parameters.

Even though

this graph represents the average of only two experiments, the general
configuration of the curve suggests that the higher the rate of DNA
synthesis, the greater the inhibition induced by asparaginase.

The

significance of this finding is difficult to determine in light of two
contradictory lines of evidence.

First, although the rate of DNA

synthesis 210 minutes post-wash in the ara-c pretreated group is lhl%
of control (Figure 5), the percentage inhibition with asparaginase in
both groups is 63% (Table A/I).
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Second, since the inhibition with

Table A/I

Effect of the post wash interval on TdR incorporation with and
without asparaginase following either saline or 10-oM ara-c for
8 hours. Asn’ase=asparaginase 0.5 IU/ml. $ Control= rate of
ara-c divided by the rate of control. Results are the average of
two experiments. Rate=dpm/10b cells/minute incubation.
Time

Group

Rate

Rate with Asn’ase ^Inhibition $ Control

90 min.

Control

17128

6993

59.2%

Ara-C

8820

4908

44.4%

Control

1806 7

6540

63. 8%

Ara-C

26763

10086

62.3$

Control

18067

6110

66.2%

Ara-C

14632

7752

47.0$

Control

17168

5905

66.6%

Ara-C

20662

6445

70.1$

Control

19377

7645

60.5$

Ara-C

19955

8395

67.9%

210 min.

6 hours

8 hours

10 hours

51.5%

148$

80.1$

120$

103$
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Figure 5: Effect of the post wash interval following ara-c
on the rate of TdR incorporation into DNA. Each point is the
average of two experiments.
(X)=normal saline (l)=ara-c
0-o =0utgrowth curve for cell number following ara-c
see figure 3*
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Figure 6: Exponetially growing L5178Y cells were treated with ara-c
for 8 hours and then the rate of DNA synthesis and the inhibitory
effect of 0.5 IU /ml of asparaginase on DNA synthesis was determined
as a function of time after removal of ara-c. (0)=Rate of DNA synthesis
(dpm/10° cells /minute incubation) .
(¥)=% inhibition with asparaginase.

Sir'

asparaginase is greater at 210 minutes in the ara-c pretreated group
than at 90 minutes, one would expect asparaginase to induce a greater
cell kill at 210 minutes.

In fact, the viability studies previously

discussed showed equivalent cytotoxicity for both time intervals
(Table III, Figure 4).

In summary, these experiments do not support

the hypothesis that ara-c potentiates the asparaginase-induced inhibi¬
tion of DNA synthesis.
An alternate hypothesis for the synergy of this combination
can be proposed based on the observation in Figure 5-

The higher

than control rate of DNA synthesis post ara-c (l4l$ of control at
210 minutes) is consistent with partial S-phase cell synchronization
and thus, a higher percentage of cells are susceptible to the effects
of a DNA synthesis inhibitor.

Therefore, since asparaginase has been

shown to inhibit DNA synthesis (24, 47, 66, 96, 148), the consequences
of an equivalent degree of inhibition on more cells should result
in greater cytotoxicity.

This argument is based, however, on the assurrp

tion that asparaginase is an S-phase specific agent.

In fact, the

literature review above Implies that the non-S-phase specific inhibi¬
tion of membrane synthesis may be a more important component of
asparaginase’s mechanism of action than is asparaginase-induced inhibi¬
tion of DNA synthesis (48, 117).

In addition, an enhanced rate of DNA

synthesis is not adequate evidence for the synchronization of tumor
cells.
In an attempt to prove that ara-c synchronizes tumor cells in
this tumor model and at this dosage, the labeling index and mitotic
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index were determined and the results presented in Table VIII.

A

labeling index of 96$ was observed for the first post-ara-c point
which is consistent with virtually a pure S-phase population.

Fur¬

thermore, the mitotic index for these cells 90 minutes post-wash
was only 0.8% and after 6 hours, when the cells were able to traverse
S-phase, the mitotic index reached a peak of 15.3$.

However, this

result is mitigated by a control labeling index of 75$ suggesting
that under these culture conditions the control cells spend threefourths of the cell cycle in S-phase.

In addition, the mitotic index

for the ara-c pretreated cells never exceeds that of the control.
This may, however, only imply that the peak mitotic index following
ara-c occurred at a time different from the data points chosen.

Even

though the data from the mitotic and labeling indexes suggest cell
synchronization with ara-c, it also implies that the L5178Y tumor
model used in these experiments is an inadequate system from which to
draw definite conclusions on the S-phase specificity of asparaginase.
Since numerous investigators have demonstrated cell synchronization
with ara-c (1, 8, 42, 85, 127, 159, 164), the investigation of the
interactions of ara-c and asparaginase in another tumor model with a
slower rate of growth migjnt be of considerable value.
In addition to demonstrating cell synchronization, the auto¬
radiographic data helps to clarify the mechanism by which ara-c causes
cell death.

Many studies as reviewed above have suggested that ara-c's

cytotoxicity is the result of competitive DNA polymerase inhibition
(51, 55, 69, 70, 101, 154).

However, other studies have shown that
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Table VII

L5178Y cells in culture were treated with ara-c 10
for 8
hours and following the removal of the drug, the labelling index
'(autoradiograms) and mitotic index were determined as a function
or time. Results represent the mean of 1000 cells counted.
Time Post Wash

Condition

Labelling Index

Mitotic Index

90 minutes

Control
Ara-C

80.8%
95.5%

7.3%
0. 8%

210 minutes

Control
Ara-C

84.0%
94.0%

8.3%
3.6%

6

hours

Control
Ara-C

82.2%
82.1%

15.9%
10.5%

8

hours

Control
Ara-C

77.9%
68.3%

10.95?
15.35S

Control
Ara-C

78.8%
85.5%

12.3%
8.3%

10 hours
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cell damage Induced by high doses of ara-c is either not reversed
or only partially reversed by dCTP.

This irreversible component of

ara-c’s action could result from failure of the DNA polymerase to
recover following removal of the drug.

However, the 96% labeling

index following ara-c’s removal shows that the DNA polymerases are
functioning in virtually all cells and despite this, only 53% of the
cells are viable by cloning (Table II).

These results support the con¬

clusions of others (32, 84, 165) that ara-cTs cytotoxicity is not ade¬
quately explained by the observed competitive inhibition of DNA poly¬
merases .
Since the data presented for the effect of asparaginase on DNA
synthesis do not completely explain the observed synergistic response,
the effect of ara-c on other macromolecules was investigated.

Al¬

though it has been reported that ara-c does not inhibit protein syn¬
thesis directly (143), the effect of ara-c pretreatment on protein
synthesis was investigated to rule out the possibility that ara-c
potentiates the inhibition of protein synthesis by asparaginase.
The effects of asparaginase on protein synthesis, 90 and 210 minutes
after removal of ara-c, is presented in Table VIII.

At 210 minutes,

asparaginase caused 84.7% inhibition in both groups.

Furthermore,

the difference between 90% inhibition for the control and 77% follow¬
ing ara-c at 90 minutes is probably not significant, but it is difficult
to draw conclusions based on a single experiment.

However, considering

both time points, it seems unlikely that ara-c profoundly effects
asparaginase’s inhibition of protein synthesis.
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Table VIII
3
Effect of post wash interval on H leucine incorporation with and
without asparaginase follwoing either saline or 10-DM ara-c for
8 hours. Data represents a single experiment. Asn'ase=asparaginase
0.5 IU/ml. Rate=dpm/10Dcells / minute incubation. % Control=
rate of ara-c divided by the rate of control.
Time

Group

Rate

Rate with Asn'ase % Inhibition % Control

90 min.

Control

1798

176

90.2%

Ara-C

1868

433

76.8%

Control

1598

245

84.7%

Ara-C

2752

422

84.7%

210 min.

104%

172%

Table IX
•3

Effect of asparaginase on H ara-c incorporation into cold acid
precipitalbe material. Data represents the mean of 4 experiments
when either saline or asparaginase(0.5 IU/ml) was added at the
beginning of a 4 hour incubation, Data is expressed as the
mean rate + 1 standard deviation. Rate =dpm/10b cells/minute incubation.

Saline
Asparaginase

158 + 11.7
60 ±

3.8

61.2$ inhibition with asparaginase

impossible from this data to exclude an interaction on a specific
protein.
In summary, the data presented for the effect of the combina¬
tion of ara-c and asparaginase on DNA and protein synthesis does not
substantiate the hypothesis that ara-c potentiates the biochemical
effects of asparaginase.

Therefore, an alternate theory must be pro¬

posed to explain why this combination is most effective in vitro
when asparaginase is added to the cells within 90 minutes of ara-c’s
removal (Table III).

The schedule dependency of this combination

suggests favorable cytokinetic timing so that asparaginase’s inhibi¬
tion of protein synthesis occurs at a critical time to the cell.
Furthermore, since the initiation of DNA synthesis requires protein
synthesis (63, 121, 140), the process of recovering from ara-c's
toxicity might be associated with an increased demand for protein
synthesis.

In fact, the results in Table VIII show that following ara-c,

the rate of protein synthesis is 172% of control at 210 minutes.
Thus in terms of cytotoxicity, these cells may be more sensitive to
an equivalent degree of inhibition with asparaginase.
Further research could be directed at elucidating which specific
proteins are required for cells to recover from ara-c and what are
the effects of asparaginase on the synthesis of these proteins.

Of

particular interest would be the effect of this combination on the
cellular levels of the « and/£ DNA polymerases.

Since the oc poly¬

merase is required for DNA replication (11, 27, 28), inhibition of its
synthesis by asparaginase would prevent the cells from reinitiating
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cell growth following ara-c.

Furthermore, if asparaginase inhibits

the synthesis of the repair enzyme,

polymerase (160), the cells

would be unable to excise the ara-c incorporated into DMA, thus
potentiating the toxicity of ara-c.
the synthesis of either oc or

0

Therefore, if asparaginase inhibited

DNA polymerase, it could explain the

schedule-dependent synergy of this combination.
Another biochemical locus that might be affected by the com¬
bination of ara-c and asparaginase is histone synthesis.

Histone

synthesis is an S-phase event that is necessary for the assembly
of newly-formed DNA complexes (131).

Boren et al. have demonstrated

a specific Inhibition of histone messenger RNA and histone synthesis
by ara-c (12, 135).

Furthermore, since asparaginase inhibits protein

synthesis (24, 47, 95, 96, 138, 147, 148, 163) probably including
inhibition of histone synthesis, the combination might produce an
additive or synergistic inhibition of histone synthesis.

Confirmation of

this hypothesis would require direct measurement of histone synthesis
following this combination.
It is also possible that the synergistic cell kill produced by
the sequential administration of ara-c and asparaginase results from
an enhanced rate of RNA catabolism.

Asparaginase might increase

the destruction of RNA as a result of higher levels of ribonuclease,
an enzyme that hydrolyses RNA.

In fact, asparaginase has been reported to

increase ribonuclease in murine lymphosarcoma P1798 (2).

Furthermore,

Boren et al. (12, 135) demonstrated that ara-c decreased the transla¬
tion of 7-9 S mRNA.

Therefore, the combination of enhanced destruction
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and decreased translation of RNA would indeed be a serious cellular
lesion.

However, this mechanism for drug synergy is only hypothetical

and further research is necessary to demonstrate that an enhanced turn¬
over of RNA indeed occurs.
The biochemical studies presented above were undertaken to explain
the observed additive or synergistic response of the sequential ad¬
ministration of ara-c followed by asparaginase, but they provide
no explanation of the antagonism of the reverse combination.

There¬

fore, a small group of experiments was done to try to understand
the observed antagonism.

Based on the hypothesis that ara-c Ts cyto¬

toxicity was associated with the incorporation of ara-c into RNA and
DNA, the effect of asparaginase treatment on ara-c's incorporation
into TCA precipitable macromolecules was investigated.

The method

used gives only the sum of the incorporation of ara-c into RNA and
DNA and does not differentiate between them.

The results presented

in Table IX confirm the findings of other investigators that ara-c
is incorporated into macromolecules (29, 32, 38, 56, 143, 166), and
that the incorporation is linear over

4 hours (Figure 7)•

Table IX

also shows that asparaginase caused a 6l% inhibition of ara-c's
incorporation into macromolecules suggesting that this may be a mech¬
anism of antagonism.

This antagonism could result from asparaginase

inhibiting the transport of ara-c into the cells as has been pre¬
viously demonstrated in the L5178Y leukemia cells by Nahas and Capizzi (107).

Following asparaginase treatment, they observed decreased

intracellular concentrations of ara-c, methotrexate, 6-mercaptopurine
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and 5-fluorouracil.

They concluded that this effect is a nonspecific

membrane defect that might result from asparaginase’s inhibition of
membrane glycoprotein synthesis.

An alternate explanation for as¬

paraginase’s antagonism of ara-c’s incorporation is that asparaginase’s
inhibition of cellular DM synthesis prevents incorporation of this
cytidine analog.
In order to differentiate between these two possible mechanisms
of antagonism, asparaginase was added to the cells after two hours
of incubation with H

ara-c, which is a tune when the intracellular

steady state concentration of ara-c should have already been reached.
Therefore, if inhibition with asparaginase occurred after this addition,
it could be assumed not to be associated with a transport defect.

The

observed change of slope of curve C in Figure 6 suggests that aspara¬
ginase directly inhibits ara-c incorporation into macromolecules
independent of a membrane effect.

However, this does not exclude

the possibility that a membrane effect might coexist.
ment represents only a preliminary study.

This experi¬

Final proof that asparaginase

antagonizes ara-c by preventing its incorporation into DM would
require the separation of the effects of asparaginase on the incor¬
poration of ara-c into DM and RM and demonstrating that the intra¬
cellular pool of ara-c is not effected by asparaginase.
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Figure 7:Effect of asparaginase on H^ara-c incorporation into cold
acid precipitable material. Data points represent the average of two
experiments.
(0)=control.
(0) =asparaginase at time 0.
(X) =asparaginase at 120 minutes as indicated by arrow.
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Summary

Ihe aim of this thesis project was to determine if the combina¬
tion of ara-c and asparaginase shows schedule-dependent synergy and/or
antagonism in the treatment of murine leukemia L5178Y.

Prior to

investigating this possibility, in vivo tumor growth curves were
determined as a basis for selecting treatment schedules.

These studies

showed that following either ara-c or asparaginase, the tumor burden
rapidly falls and does not begin to recover until 120 hours post¬
treatment.

Consequently, a 120 hour interval was chosen between

drugs for the sequential treatment schedules in the animal survival
studies.

The mouse studies demonstrated that the sequential use of

ara-c and then asparaginase resulted in synergistic animal survival.
However, when asparaginase preceded ara-c or when both drugs were
administered simultaneously, a subadditive or antagonistic response
was observed.
The schedule-dependent synergy and antagonism observed in vivo
for the combination of ara-c and asparaginase was investigated further
in vitro by cell viability studies.

As before, an antagonistic response

was observed for the sequential use of asparaginase and then ara-c
and for the simultaneous treatment with both drugs.

Furthermore,

an additive, if not synergistic, response occurred following the
sequential treatment with ara-c and then asparaginase, but this favorable
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response was lost when the interval between drugs exceeded 90 minutes.
The observation confirms the in vivo data and supports the importance
of understanding drug-drug interactions.
In an attempt to explain the observed synergy, the effect of
the sequential administration of ara-c and then asparaginase on
macromolecular synthesis in vitro was explored.

Ara-c pretreatment

did not potentiate the asparaginase-induced inhibition of DM syn¬
thesis.

Furthermore, this lack of potentiation was not influenced

by different doses of ara-c or by the time interval betewen ara-c
and asparaginase.

In addition, ara-c did not potentiate the effect

of asparaginase on protein synthesis.
A

An enhanced rat ft of DM and protein synthesis, as compared to
A

control,was observed 210 minutes after ara-c*s removal.

This observa¬

tion is consistent with ara-c induced partial cell synchronization and
is supported in part by the results of the labeling and mitotic in¬
dices.

However, in this tumor model the increase in S-phase cells fol¬

lowing ara-c is too small to account for the synergistic effect of the
combination.

Although no definitive mechanism can be proposed to ex¬

plain the observed synergistic response, it seems most likely that
asparaginase is preventing the tumor cells from recovering from ara-c*s
toxicity.

Further implications of this and other mechanisms are

discussed.
Finally, data is presented that shows that asparaginase prevents
ara-c*s incorporation into macromolecules.

Since ara-c*s incorpora¬

tion into macromolecules is associated with its cytotoxicity.
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inhibition of its incorporation could explain the antagonism of the se¬
quential use of asparaginase and then ara-c.
It is hoped that the use of this data to devise a new treatment
protocol for acute leukemia will result in an enhanced therapeutic
response and in the prolongation of a human life.
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